![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » J&J Licenses Hep B Treatments from Chia Tai Tianqing
J&J Licenses Hep B Treatments from Chia Tai Tianqing
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/JohnsonJohnsonInnovation_Logo.gif?t=1453402838&width=430)
January 13, 2016
In a rare move, Johnson & Johnson Innovation and Janssen Pharmaceuticals have in-licensed products from a Chinese drugmaker to develop drugs outside that country.
The deal with Chia Tai Tianqing Pharmaceutical Group gives J&J exclusive rights to develop, manufacture and commercialize undisclosed immune-modulating agents for a number of conditions — including chronic hepatitis B — outside China. Financial terms of the deal were not disclosed.
Upcoming Events
-
21Oct